scholarly journals Dynamic Contrast-enhanced MR Imaging in Renal Cell Carcinoma: Reproducibility of Histogram Analysis on Pharmacokinetic Parameters

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Hai-yi Wang ◽  
Zi-hua Su ◽  
Xiao Xu ◽  
Zhi-peng Sun ◽  
Fei-xue Duan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Mr Imaging ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Histogram Analysis ◽  
Pharmacokinetic Parameters ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

scholarly journals Dynamic Contrast-enhanced MR Imaging for Differentiation of Renal Cell Carcinoma Subtypes: Myth or Reality?

Radiology ◽  
2009 ◽  
Vol 252 (3) ◽  
pp. 929-931 ◽  
Author(s):  
Michele Scialpi ◽  
Luca Brunese ◽  
Irene Piscioli ◽  
Antonio Rotondo
Keyword(s):  
Renal Cell Carcinoma ◽  
Mr Imaging ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

Renal Cell Carcinoma: Dynamic Contrast-enhanced MR Imaging for Differentiation of Tumor Subtypes—Correlation with Pathologic Findings

Radiology ◽  
2009 ◽  
Vol 250 (3) ◽  
pp. 793-802 ◽  
Author(s):  
Maryellen R. M. Sun ◽  
Long Ngo ◽  
Elizabeth M. Genega ◽  
Michael B. Atkins ◽  
Myra E. Finn ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Mr Imaging ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Subtypes ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
Pathologic Findings

Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4580-4580
Author(s):  
Durga Udayakumar ◽  
Ze Zhang ◽  
Durgesh Dwivedi ◽  
Yin Xi ◽  
Tao Wang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Molecular Heterogeneity ◽  
Cell Renal Cell Carcinoma ◽  
Post Contrast ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

4580 Background: Mutation/inactivation of VHL in clear cell renal cell carcinoma (ccRCC) leads to upregulation of hypoxia inducible factors ( HIFs) and angiogenesis. However, ccRCC is characterized by high intra-tumor heterogeneity (ITH). Random small samples such as those in percutaneous biopsies are likely limited for characterization of molecular alterations in heterogeneous ccRCCs. We hypothesize that whole-tumor dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is useful to noninvasively identify ITH in ccRCC. Methods: This IRB-approved, prospective, HIPAA-compliant study, included 62 ccRCCs. 3T DCE MRI was obtained prior to nephrectomy. Surgical specimens were sectioned to match MRI acquisition plane. 182 snap frozen samples (49 tumors) and adjacent uninvolved renal parenchyma (URP) were collected. RNA isolations, cDNA library preparation and mRNA sequencing were performed using standard protocols. RNA expression in 81 tumor samples were correlated (Spearman ranked) with % enhancement in a region of interest (ROI) drawn in the same location of the tumor on pre- and 3 different post-contrast DCE MRI phases. Gene function overrepresentation (OR) analyses were done on top positively and negatively correlated genes. False discovery rate (FDR) < 0.1 was considered statistically significant. Results: Principal component analysis of > 20,000 genes indicated distinct gene expression in tumors from URP. Unsupervised clustering showed enrichment of ccA samples (better prognosis) compared to ccB samples (worse prognosis). Importantly, ccA and ccB samples coexisted in 25% of tumors. DCE-MRI % enhancement correlated with expression of > 300 genes (p < 0.003, FDR < 0.1). OR analyses placed angiogenic pathway gene processes and the immune/inflammatory response processes within the top 5 positively- and negatively-correlated gene functions, respectively. HIF2 target genes correlated positively with % enhancement. Conclusions: DCE MRI detects specific molecular signatures and may help overcome the challenges of ITH in ccRCC. Further research is needed to explore the potential role of DCE MRI to assess response to antiangiogenic and immune-based therapies.

Sign in / Sign up

Export Citation Format

Share Document